Prolia Shortage Update: What Patients Need to Know in 2026

If you take Prolia (denosumab) for osteoporosis and have been worried about whether you'll be able to get your next injection, you're not alone. Many patients search for "Prolia shortage" — and while Prolia is not on the FDA's official drug shortage list in 2026, real-world supply disruptions can and do affect individual patients. Here's what you need to know.

Current Prolia Shortage Status (2026)

As of 2026, Prolia (denosumab) manufactured by Amgen is NOT listed on the FDA Drug Shortage Database. National supply is generally stable. However, this doesn't mean every patient will get their injection without friction. Local, practice-level, and insurance-related disruptions remain common — and the consequences of missing a Prolia dose are more serious than with most other medications.

Why Prolia Delays Still Happen Even Without a Shortage

Unlike pills that sit on pharmacy shelves, Prolia must be ordered by your provider, shipped through a specialty distributor, and administered in a clinical setting. Delays can happen at several points in this chain:

• Insurance prior authorization lapses: Prior auth approvals often expire annually. If your provider doesn't renew in time, your injection can be delayed by weeks.
• Formulary biosimilar switches: Many plans, including some UnitedHealthcare Medicare Advantage plans as of September 2025, have replaced Prolia with biosimilars like Jubbonti on their formularies. If your office is still ordering brand Prolia, you may face coverage denial.
• Specialty distributor delays: Small practices may experience shipping delays, particularly in rural areas.
• Office ordering failures: Some practices order Prolia reactively (only when a patient calls) rather than proactively, leading to short-notice supply gaps.

The Biosimilar Revolution: Nine New Denosumab Products in 2026

One of the most significant developments in the Prolia market is the explosion of FDA-approved biosimilars. From March 2024 through March 2026, nine denosumab biosimilars received FDA approval:

• Jubbonti (denosumab-bbdz) — Sandoz, approved March 2024
• Bomyntra (denosumab-bnht) — Fresenius Kabi, approved March 2025
• Enoby (denosumab-qbde) — approved September 2025
• Osvyrti (denosumab-desu) — approved October 2025
• Boncresa (denosumab-mobz) — Amneal, approved December 2025
• Ponlimsi (denosumab-adet) — approved March 2026

These biosimilars are therapeutically equivalent to Prolia. While the transition is creating some short-term administrative confusion, long-term they mean greater supply and lower costs for patients.

Why Missing a Prolia Dose Is Especially Dangerous

This is worth repeating: Prolia is different from most medications in that stopping treatment — even briefly — triggers a rebound effect. When denosumab is discontinued, bone resorption can spike to levels significantly above baseline, dramatically increasing the risk of vertebral fractures. The FDA added language to Prolia's label specifically warning about multiple vertebral fractures following discontinuation.

What to Do If You're Having Trouble Getting Prolia in 2026

Here are action steps you can take right now:

1. Call your provider's office 4–6 weeks before your next injection is due to confirm drug availability and insurance authorization.
2. Ask whether your insurance now requires a biosimilar, and if so, whether your office can order it.
3. If your office can't provide the injection, ask for a referral to a rheumatology practice or infusion center nearby.
4. Contact Amgen SupportPlus (1-866-264-2778) for help navigating supply and insurance challenges.

You can also use medfinder to find providers near you who can administer Prolia or a denosumab biosimilar. We call ahead so you don't have to.

Learn more: Alternatives to Prolia If You Can't Fill Your Prescription.